The monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib are currently clinical therapies targeting HER2 65, 66, however, adaptive resistance to anti‐HER2 therapy also occurrs in HER2‐positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.